Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

123Citations
Citations of this article
93Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.

Cite

CITATION STYLE

APA

Seftel, D., & Boulware, D. R. (2021, February 1). Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19. Open Forum Infectious Diseases. Oxford University Press. https://doi.org/10.1093/ofid/ofab050

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free